Literature DB >> 19533761

Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications.

Maxime J J Fleury1, Antoine Touzé, Marie-Christine Maurel, Thierry Moreau, Pierre Coursaget.   

Abstract

The aim of this study was to characterize the conformational neutralizing epitopes of the major capsid protein of human papillomavirus type 31. Analysis of the epitopes was performed by competitive epitope mapping using 15 anti-HPV31 and by reactivity analysis using a HPV31 mutant with an insertion of a seven-amino acid motif within the FG loop of the capsid protein. Fine mapping of neutralizing conformational epitopes on HPV L1 was analyzed by a new approach using a system displaying a combinatorial library of constrained peptides exposed on E. coli flagella. The findings demonstrate that the HPV31 FG loop is dense in neutralizing epitopes and suggest that HPV31 MAbs bind to overlapping but distinct epitopes on the central part of the FG loop, in agreement with the exposure of the FG loop on the surface of HPV VLPs, and thus confirming that neutralizing antibodies are mainly located on the tip of capsomeres. In addition, we identified a crossreacting and partially crossneutralizing conformational epitope on the relatively well conserved N-terminal part of the FG loop. Moreover, our findings support the hypothesis that there is no correlation between neutralization and the ability of MAbs to inhibit VLP binding to heparan sulfate, and confirm that the blocking of virus attachment to the extracellular matrix is an important mechanism of neutralization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19533761      PMCID: PMC2775211          DOI: 10.1002/pro.156

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  70 in total

1.  Structure-based identification of a major neutralizing site in an adenovirus hexon.

Authors:  Susan L Pichla-Gollon; Mark Drinker; Xiangyang Zhou; Feng Xue; John J Rux; Guang-Ping Gao; James M Wilson; Hildegund C J Ertl; Roger M Burnett; Jeffrey M Bergelson
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

2.  Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies.

Authors:  Brooke Bishop; Jhimli Dasgupta; Michael Klein; Robert L Garcea; Neil D Christensen; Rui Zhao; Xiaojiang S Chen
Journal:  J Biol Chem       Date:  2007-09-04       Impact factor: 5.157

3.  Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells.

Authors:  Nicolas Chomont; Hakim Hocini; Jean-Chrysostome Gody; Hicham Bouhlal; Pierre Becquart; Corinne Krief-Bouillet; Michel Kazatchkine; Laurent Bélec
Journal:  Virology       Date:  2007-10-24       Impact factor: 3.616

4.  Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.

Authors:  Patricia M Day; Cynthia D Thompson; Christopher B Buck; Yuk-Ying S Pang; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

5.  Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate.

Authors:  Maren Knappe; Sabrina Bodevin; Hans-Christoph Selinka; Dorothe Spillmann; Rolf E Streeck; Xiaojiang S Chen; Ulf Lindahl; Martin Sapp
Journal:  J Biol Chem       Date:  2007-07-18       Impact factor: 5.157

6.  Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus.

Authors:  Hans-Christoph Selinka; Luise Florin; Hetal D Patel; Kirsten Freitag; Michaela Schmidtke; Vadim A Makarov; Martin Sapp
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

7.  Human papillomavirus type 31 uses a caveolin 1- and dynamin 2-mediated entry pathway for infection of human keratinocytes.

Authors:  Jessica L Smith; Samuel K Campos; Michelle A Ozbun
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

8.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.

Authors:  Jeffrey N Roberts; Christopher B Buck; Cynthia D Thompson; Rhonda Kines; Marcelino Bernardo; Peter L Choyke; Douglas R Lowy; John T Schiller
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

9.  Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.

Authors:  Kevin A Ault
Journal:  Lancet       Date:  2007-06-02       Impact factor: 79.321

10.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Authors:  Jorma Paavonen; David Jenkins; F Xavier Bosch; Paulo Naud; Jorge Salmerón; Cosette M Wheeler; Song-Nan Chow; Dan L Apter; Henry C Kitchener; Xavier Castellsague; Newton S de Carvalho; S Rachel Skinner; Diane M Harper; James A Hedrick; Unnop Jaisamrarn; Genara Am Limson; Marc Dionne; Wim Quint; Bart Spiessens; Pascal Peeters; Frank Struyf; Susan L Wieting; Matti O Lehtinen; Gary Dubin
Journal:  Lancet       Date:  2007-06-30       Impact factor: 79.321

View more
  15 in total

Review 1.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Epitope mapping of Borrelia burgdorferi OspC protein in homodimeric fold.

Authors:  Adam Norek; Lubomír Janda
Journal:  Protein Sci       Date:  2017-02-11       Impact factor: 6.725

3.  Human papillomavirus type 16 pseudovirions with few point mutations in L1 major capsid protein FG loop could escape actual or future vaccination for potential use in gene therapy.

Authors:  Maxime J J Fleury; Antoine Touzé; Pierre Coursaget
Journal:  Mol Biotechnol       Date:  2014-05       Impact factor: 2.695

4.  Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.

Authors:  Sara L Bissett; Anna Godi; Maxime J J Fleury; Antoine Touze; Clementina Cocuzza; Simon Beddows
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

5.  Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials.

Authors:  Joseph E Tota; Frank Struyf; Joshua N Sampson; Paula Gonzalez; Martin Ryser; Rolando Herrero; John Schussler; Naveen Karkada; Ana Cecilia Rodriguez; Nicolas Folschweiller; Carolina Porras; Mark Schiffman; John T Schiller; Wim Quint; Aimée R Kreimer; Cosette M Wheeler; Allan Hildesheim
Journal:  J Natl Cancer Inst       Date:  2020-08-01       Impact factor: 13.506

6.  Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines.

Authors:  Anna Godi; Alessandra Facchetti; Sara L Bissett; Clementina Cocuzza; Elizabeth Miller; Simon Beddows
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

7.  Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.

Authors:  Anna Godi; Dolcibella Boampong; Busayo Elegunde; Kavita Panwar; Maxime Fleury; Shaowei Li; Qinjian Zhao; Ningshao Xia; Neil D Christensen; Simon Beddows
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

8.  Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.

Authors:  Ariana Harari; Zigui Chen; Ana Cecilia Rodríguez; Allan Hildesheim; Carolina Porras; Rolando Herrero; Sholom Wacholder; Orestis A Panagiotou; Brian Befano; Robert D Burk; Mark Schiffman
Journal:  J Infect Dis       Date:  2015-10-30       Impact factor: 5.226

9.  Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.

Authors:  Kihyuck Kwak; Rosie Jiang; Subhashini Jagu; Joshua W Wang; Chenguang Wang; Neil D Christensen; Richard B S Roden
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

10.  Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.

Authors:  Amina I Ahmed; Sara L Bissett; Simon Beddows
Journal:  Infect Genet Evol       Date:  2013-05-27       Impact factor: 3.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.